Selected publications
-
A phase I, Dose escalation study of oral ASP8273 in patients with non–small cell lung cancers with epidermal growth factor receptor mutations.
Clinical Cancer Research.
2017
Academic Article
GET IT
Times cited: 16 -
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial.
The Lancet Oncology.
2016
Academic Article
GET IT
Times cited: 177 -
Scientific advances in lung cancer 2015.
Journal of Thoracic Oncology.
2016
Review
GET IT
Times cited: 111 -
Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: A brief report.
Journal of Thoracic Oncology.
2014
Academic Article
GET IT
Times cited: 16 -
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial.
The Lancet Oncology.
2014
Academic Article
GET IT
Times cited: 66 -
HER2 mutations in non-small-cell lung cancer can be continually targeted.
Journal of Clinical Oncology.
2012
Letter
GET IT
Times cited: 20 -
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Clinical Cancer Research.
2012
Academic Article
GET IT
Times cited: 113 -
Thymic malignancies: From clinical management to targeted therapies.
Journal of Clinical Oncology.
2011
Review
GET IT
Times cited: 74 -
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Clinical Cancer Research.
2011
Academic Article
GET IT
Times cited: 83 -
Lung cancer vaccines.
Cancer Journal.
2011
Article
GET IT
Times cited: 28 -
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
Journal of Clinical Oncology.
2011
Academic Article
GET IT
Times cited: 109 -
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Clinical Cancer Research.
2011
Academic Article
GET IT
Times cited: 54 -
Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.
Journal of Clinical Oncology.
2010
Academic Article
GET IT
Times cited: 38 -
The role of talactoferrin alfa in the treatment of non-small cell lung cancer.
Expert Opinion on Biological Therapy.
2010
Review
GET IT
Times cited: 16 -
Thymoma-associated paraneoplastic polymyositis.
Journal of Clinical Oncology.
2010
Article
GET IT
Times cited: 7 -
Small-molecule inhibitors of the human epidermal receptor family.
Expert Opinion on Investigational Drugs.
2009
Review
GET IT
Times cited: 24 -
Antiangiogenesis induced tumor cavitation in lung cancer.
Journal of Thoracic Oncology.
2009
Academic Article
GET IT
Times cited: 1 -
Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer.
Clinical Colorectal Cancer.
2005
Review
GET IT
Times cited: 29